Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort study
Main finding · MelanomaResult — go to the resultHazard ratio 0.96 95% CI 0.53–1.75Authors' conclusion
In this population-based cohort study, GLP-1 RAs were not associated with an increased risk of melanoma or nonmelanoma skin cancer, compared with sulfonylureas.
Study context
- Population
- Patients with T2D, UK Clinical Practice Research Datalink (2007–2019)two cohorts
- Exposure
- GLP-1 RAs vs sulfonylureas
- Outcome
- Melanoma and nonmelanoma skin cancer, separately
Methodological detailsnew-user active comparator, propensity score fine stratification weighting
- New-user active comparator
- Propensity score fine stratification weighting
Main finding
Melanoma
Hazard ratio
0.96
95% CI 0.53–1.75
By group
GLP-1 RAs
42.6 per 100,000 person-years
Sulfonylureas
43.9 per 100,000 person-years
GLP-1 RAsvs Sulfonylureas
HR 0.96 (95% CI 0.53–1.75)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1 RAs | Sulfonylureas | HR (95% CI) | |
|---|---|---|---|---|
| Nonmelanoma skin cancer | 243.9 per 100,000 person-years | 229.9 per 100,000 person-years | 1.03 (0.80–1.33) | |
| 0.512Hazard ratio (log scale) |
- Nonmelanoma skin cancer: co-primary outcome; nonmelanoma cohort: 11,774 GLP-1 RA vs 207,788 sulfonylurea new users
Cumulative duration of use
- No evidence of an association between cumulative duration of use and melanoma or nonmelanoma skin cancer
Secondary and sensitivity analyses
- Consistent results
Original publication
Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort study. Diabet Med. Published 10 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →